Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and the toxicities of the study drug
PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype
retinoblastoma protein (RB) and inactivated cyclin dependent kinase (CDK) N2A in the tumor.